News

AddToAny

Google+ Facebook Twitter Twitter

Test distinguishes SARS-CoV-2

A tablet-sized device has been developed that can detect multiple COVID-19 antibodies and biomarkers simultaneously.

Initial results show it can distinguish between antibodies produced in response to SARS-CoV-2 and four other coronaviruses with 100% accuracy. The team behind the device are now working to see if the point-of-care device can be used to predict the severity of a COVID-19 infection or a person’s immunity against variants of the virus.

Having also recently shown the same “D4 assay” platform can detect Ebola infections a day earlier than the gold standard polymerase chain reaction (PCR) test, the researchers say the results show how flexible the technology can be.

The platform hinges on a polymer brush coating that stops anything but the desired biomarkers from attaching to the test slide when wet.

bit.ly/2Ue26Sz

 

Image Credit | Duke University

 

Related Articles

The great big biomedical science quiz: 2021 roundup

As we say goodbye to 2021, we finish the year with two rounds of questions to test members’ knowledge on the pandemic and science headlines from the last 12 months. (Scroll to the bottom for a link to the answers.)

The science of nephrotoxicity

Shahid Nazir Muhammad, Academic and Chartered Scientist, and Claire Corps, Research and Clinical Scientist, give an overview of how kidney transplants in paediatrics can survive with immunosuppression therapy.

Under the microscope: Fomitopsis officinalis

This month: Fomitopsis officinalis

Trial campaign to reduce opioids "is effective"

A campaign that urged GPs to “think twice” before putting a patient on opioid medicines is effective in reducing opioid prescribing in primary care, according to a major study.

Top